Trial Outcomes & Findings for An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy (NCT NCT01602120)

Last Updated: 2019-09-11

Results Overview

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are events localized to the eye. Non-ocular events include all other events.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

159 participants

Primary outcome timeframe

From Day 1 up to the last study visit (up to approximately 62 months)

Results posted on

2019-09-11

Participant Flow

This study enrolled eligible patients who had completed the 18-month treatment period of Study NCT01229215 (CFD4870g) or the 24-week treatment period of Study NCT02288559 (GX29455). The study was terminated early by the Sponsor due to lack of efficacy.

Participant milestones

Participant milestones
Measure	CFD4870g Sham Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.
Overall Study STARTED	29	60	17	53
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	29	60	17	53

Reasons for withdrawal

Reasons for withdrawal
Measure	CFD4870g Sham Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.
Overall Study Adverse Event	3	6	0	2
Overall Study Death	0	4	0	0
Overall Study Lost to Follow-up	0	1	0	1
Overall Study Protocol Violation	1	1	0	0
Overall Study Non-compliance	0	3	0	1
Overall Study Withdrawal by Subject	8	17	0	3
Overall Study Study Terminated by Sponsor	12	24	17	44
Overall Study Physician Decision	2	3	0	0
Overall Study Unspecified Reason	3	1	0	2

Baseline Characteristics

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	CFD4870g Sham n=29 Participants Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab n=60 Participants Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham n=17 Participants Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab n=53 Participants Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	Total n=159 Participants Total of all reporting groups
Age, Continuous	79.4 years STANDARD_DEVIATION 6.6 • n=5 Participants	79.4 years STANDARD_DEVIATION 6.8 • n=7 Participants	76.7 years STANDARD_DEVIATION 6.6 • n=5 Participants	79.5 years STANDARD_DEVIATION 7.6 • n=4 Participants	79.1 years STANDARD_DEVIATION 7.0 • n=21 Participants
Sex: Female, Male Female	17 Participants n=5 Participants	33 Participants n=7 Participants	12 Participants n=5 Participants	27 Participants n=4 Participants	89 Participants n=21 Participants
Sex: Female, Male Male	12 Participants n=5 Participants	27 Participants n=7 Participants	5 Participants n=5 Participants	26 Participants n=4 Participants	70 Participants n=21 Participants
Race/Ethnicity, Customized Hispanic or Latino	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	29 Participants n=5 Participants	59 Participants n=7 Participants	17 Participants n=5 Participants	52 Participants n=4 Participants	157 Participants n=21 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized White	29 Participants n=5 Participants	59 Participants n=7 Participants	15 Participants n=5 Participants	53 Participants n=4 Participants	156 Participants n=21 Participants

PRIMARY outcome

Timeframe: From Day 1 up to the last study visit (up to approximately 62 months)

Population: Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study.

Outcome measures

Outcome measures
Measure	CFD4870g Sham n=29 Participants Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab n=60 Participants Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham n=17 Participants Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab n=53 Participants Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	All Participants n=159 Participants All participants in the study received lampalizumab 10 mg, ITV, Q4W.
Percentage of Participants With Ocular and Non-ocular Adverse Events (AEs) Ocular AEs in Study Eye	62.1 percentage of participants	78.3 percentage of participants	52.9 percentage of participants	50.9 percentage of participants	63.5 percentage of participants
Percentage of Participants With Ocular and Non-ocular Adverse Events (AEs) Ocular AEs in Fellow Eye	62.1 percentage of participants	68.3 percentage of participants	29.4 percentage of participants	60.4 percentage of participants	60.4 percentage of participants
Percentage of Participants With Ocular and Non-ocular Adverse Events (AEs) Non-Ocular AEs	79.3 percentage of participants	90.0 percentage of participants	82.4 percentage of participants	67.9 percentage of participants	79.9 percentage of participants

Adverse Events

CFD4870g Sham

Serious events: 16 serious events

Other events: 24 other events

Deaths: 1 deaths

CFD4870g Lampalizumab

Serious events: 40 serious events

Other events: 56 other events

Deaths: 6 deaths

GX29455 Sham

Serious events: 5 serious events

Other events: 16 other events

Deaths: 0 deaths

GX29455 Lampalizumab

Serious events: 9 serious events

Other events: 41 other events

Deaths: 1 deaths

All Participants

Serious events: 70 serious events

Other events: 137 other events

Deaths: 8 deaths

Serious adverse events

Serious adverse events
Measure	CFD4870g Sham n=29 participants at risk Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab n=60 participants at risk Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham n=17 participants at risk Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab n=53 participants at risk Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	All Participants n=159 participants at risk All participants in the study received lampalizumab 10 mg, ITV, Q4W.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Dehydration	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Psychiatric disorders Mental status changes	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Reproductive system and breast disorders Pelvic pain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Blood and lymphatic system disorders Anaemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Endocrine disorders Thyroid mass	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Asthenia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Catheter site haemorrhage	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Chest pain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Death	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Fatigue	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Peripheral swelling	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Pyrexia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Acute coronary syndrome	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Angina pectoris	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Atrial fibrillation	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Atrioventricular block second degree	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Cardiac failure congestive	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Cardiac perforation	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Coronary artery disease	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Ischaemic cardiomyopathy	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Myocardial infarction	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Sinus node dysfunction	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Supraventricular tachycardia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Ventricle rupture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Ventricular tachycardia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Blindness transient	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Cataract	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Eye haemorrhage	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Retinal detachment	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Visual acuity reduced	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Visual impairment	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Vitritis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Cellulitis	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Diverticulitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Endophthalmitis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Escherichia sepsis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Infected lymphocele	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Pneumonia	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Pneumonia bacterial	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Sepsis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Septic shock	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Urinary tract infection	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Urosepsis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Craniocerebral injury	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Fall	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Foreign body aspiration	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Genital injury	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Limb injury	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Pubis fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Rib fracture	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Vascular pseudoaneurysm	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Investigations Intraocular pressure increased	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Costochondritis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma pancreas	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leukaemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage III	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of lung	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Carotid artery stenosis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Cerebrovascular accident	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Epilepsy	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Hydrocephalus	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Hypoaesthesia	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Ischaemic stroke	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Syncope	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Transient ischaemic attack	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Asthma	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Pneumothorax	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Pneumothorax spontaneous	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Deep vein thrombosis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Hypertension	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Varicose vein	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Renal and urinary disorders Nephrolithiasis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Dysphagia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Gastric ulcer haemorrhage	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Impaired gastric emptying	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Hepatobiliary disorders Bile duct stone	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.

Other adverse events

Other adverse events
Measure	CFD4870g Sham n=29 participants at risk Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), received lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study.	CFD4870g Lampalizumab n=60 participants at risk Participants received lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study.	GX29455 Sham n=17 participants at risk Participants who were administered sham comparator in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	GX29455 Lampalizumab n=53 participants at risk Participants who were administered lampalizumab in Study NCT02288559 (GX29455), received lampalizumab 10 mg, ITV, Q4W throughout the extension study.	All Participants n=159 participants at risk All participants in the study received lampalizumab 10 mg, ITV, Q4W.
Blood and lymphatic system disorders Anaemia	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Atrial fibrillation	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	16.7% 10/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	9.4% 15/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Coronary artery disease	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Cardiac disorders Cardiac failure congestive	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Ear and labyrinth disorders Vertigo positional	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Conjunctival haemorrhage	13.8% 4/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	30.0% 18/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	17.6% 3/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	17.6% 28/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Retinal haemorrhage	13.8% 4/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	21.7% 13/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.8% 2/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	13.8% 22/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Eye pain	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	23.3% 14/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	13.2% 21/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Cataract	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	15.0% 9/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	9.4% 5/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	9.4% 15/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Posterior capsule opacification	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.8% 2/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	9.4% 5/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.2% 13/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Vitreous detachment	13.8% 4/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.3% 6/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 12/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Vitreous floaters	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	10.0% 6/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 12/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Dry eye	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	10.0% 6/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.9% 11/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Punctate keratitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.7% 7/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.8% 2/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.9% 11/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Visual impairment	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 9/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Cataract nuclear	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 8/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Blepharitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Neovascular age-related macular degeneration	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Vision blurred	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Iritis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Blindness transient	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Cataract subcapsular	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Dry age-related macular degeneration	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Eye pruritus	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Lacrimation increased	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Ocular hyperaemia	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Foreign body sensation in eyes	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Visual acuity reduced	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Blepharochalasis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Conjunctival hyperaemia	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Ocular hypertension	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Open angle glaucoma	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Trichiasis	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Corneal erosion	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Corneal opacity	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Vitreous haemorrhage	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Corneal oedema	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Eyelid ptosis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Eye disorders Macular oedema	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Constipation	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	15.0% 9/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.2% 13/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Diarrhoea	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.7% 7/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.3% 10/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Nausea	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 8/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Gastrooesophageal reflux disease	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Gastrointestinal disorders Gastritis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Oedema peripheral	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 8/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Pain	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Asthenia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
General disorders Injection site pain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Immune system disorders Seasonal allergy	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Immune system disorders Drug hypersensitivity	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Nasopharyngitis	27.6% 8/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	18.3% 11/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	15.1% 24/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Urinary tract infection	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	21.7% 13/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	13.2% 21/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Upper respiratory tract infection	13.8% 4/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	15.0% 9/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	17.6% 3/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 4/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	12.6% 20/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Bronchitis	17.2% 5/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.7% 7/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.8% 14/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Sinusitis	13.8% 4/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.9% 11/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Pneumonia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	10.0% 6/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 9/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Herpes zoster	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Influenza	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	10.0% 6/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Cystitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Ear infection	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Conjunctivitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Tooth infection	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Cellulitis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Diverticulitis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Infections and infestations Oral herpes	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Fall	24.1% 7/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	21.7% 13/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	17.6% 3/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	15.7% 25/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Contusion	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Procedural pain	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Corneal abrasion	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Laceration	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Rib fracture	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Muscle strain	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Skin abrasion	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Injury, poisoning and procedural complications Forearm fracture	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Investigations Intraocular pressure increased	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	10.0% 6/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 3/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	7.5% 12/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Investigations Blood glucose increased	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Hypercholesterolaemia	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Metabolism and nutrition disorders Diabetes mellitus	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Arthralgia	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 9/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Back pain	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 8/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Arthritis	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Pain in extremity	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	4.4% 7/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Sjogren's syndrome	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Foot deformity	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Bone swelling	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Musculoskeletal and connective tissue disorders Metatarsalgia	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	10.3% 3/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of skin	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Hypotension	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Blepharal papilloma	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Headache	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	13.3% 8/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.7% 9/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Dementia	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Dizziness	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Neuropathy peripheral	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Paraesthesia	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Nervous system disorders Migraine	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Psychiatric disorders Depression	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 6/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Psychiatric disorders Anxiety	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.8% 2/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Psychiatric disorders Hallucination, visual	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Renal and urinary disorders Haematuria	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.7% 4/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Cough	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	8.3% 5/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 8/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.0% 3/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.1% 5/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	3.3% 2/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	2.5% 4/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Skin and subcutaneous tissue disorders Ingrowing nail	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.7% 1/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 3/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Skin and subcutaneous tissue disorders Hyperkeratosis	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Skin and subcutaneous tissue disorders Skin ulcer	3.4% 1/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.3% 2/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Surgical and medical procedures Cataract operation	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Hypertension	6.9% 2/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	11.7% 7/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	1.9% 1/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	6.9% 11/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.
Vascular disorders Peripheral vascular disorder	0.00% 0/29 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/60 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	5.9% 1/17 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.00% 0/53 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.	0.63% 1/159 • From Day 1 up to the last study visit (up to approximately 62 months) At the time of study enrollment, if the participant had any ongoing adverse events from Study NCT01229215 (CFD4870g) or NCT02288559 (GX29455) these events were counted in this study. Safety population included all participants who were enrolled and received at least one lampalizumab injection in the extension study. The arm All Participants reports all adverse events that occurred in the four arms in the study.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800 821 - 8590

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER